| Companies sponsors |
AstraZeneca UK (acalabrutinib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
African Caribbean Leukaemia Trust |
| |
Anthony Nolan |
| |
Black Health Agency for Equality |
| |
Blood Cancer UK |
| |
Cancer 52 |
| |
Cancer Black Care |
| |
Chronic Lymphocytic Leukaemia Support Association |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients Voice |
| |
Kevin Kararwa Leukaemia Trust |
| |
Leukaemia Cancer Society |
| |
Leukaemia Care |
| |
Leukaemia UK |
| |
Lymphoma Action |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| |
WMUK |
| Professional groups |
Association of Anaesthetists |
| |
Association of Cancer Physicians |
| |
Association of Surgeons of Great Britain and Ireland |
| |
British Blood Transfusion Society |
| |
British Geriatrics Society |
| |
British Institute of Radiology |
| |
British Oncology Pharmacy Association |
| |
British Psychosocial Oncology Society |
| |
British Society for Haematology |
| |
British Society of Blood and Marrow Transplantation and Cellular Therapy |
| |
British Society of Interventional Radiology |
| |
British Transplantation Society |
| |
Cancer Research UK |
| |
NHS Blood and Transplant |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiographers |
| |
UK Clinical Pharmacy Association |
| |
UK CLL forum |
| |
UK Oncology Nursing Society |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
AbbVie (venetoclax) |
| |
Accord (bendamustine, fludarabine) |
| |
Aspen (chlorambucil) |
| |
Baxter Healthcare (cyclophosphamide) |
| |
BeOne Medicines UK (zanubrutinib) |
| |
Celltrion Healthcare UK (rituximab) |
| |
Dr Reddy’s Laboratories (bendamustine) |
| |
Gilead Sciences (idelalisib) |
| |
Johnson & Johnson Innovative Medicine (ibrutinib) |
| |
Pfizer (rituximab) |
| |
Roche (obinutuzumab, rituximab) |
| |
Sandoz (cyclophosphamide, rituximab) |
| |
Sanofi (fludarabine) |
| |
Seacross Pharmaceuticals (bendamustine) |
| |
Zentiva (bendamustine) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Hospital Information Services –Jehovah’s Witnesses |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| Relevant research groups |
Cochrane Haematological Group |
| |
Genomics England |
| |
Institute of Cancer Research |
| |
Leukaemia Busters |
| |
Lymphoma Research Trust |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |